Braasch Biotech LLC is a privately held American company that specializes in the development of biopharmaceutical

vaccine A vaccine is a biological Dosage form, preparation that provides active acquired immunity to a particular infectious disease, infectious or cancer, malignant disease. The safety and effectiveness of vaccines has been widely studied and verifi ...

products for the human and veterinary healthcare markets. Specifically, Braasch has developed the world's first anti-

obesity Obesity is a medical condition, considered by multiple organizations to be a disease, in which excess Adipose tissue, body fat has accumulated to such an extent that it can potentially have negative effects on health. People are classifi ...

vaccine. They are also researching applications for Growth Hormone Deficiency and Type 2

diabetes Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or the cells of th ...

markets.

History

In 2008, Braasch Biotech LLC was incorporated in the State of

South Dakota South Dakota (; Sioux language, Sioux: , ) is a U.S. state, state in the West North Central states, North Central region of the United States. It is also part of the Great Plains. South Dakota is named after the Dakota people, Dakota Sioux ...

. Their total focus was on developing Somatostatin vaccines and related technology. In addition to developing and testing its Somatostatin vaccine technology in a variety of species and for different metabolic conditions, the company has also expanded its worldwide intellectual property positions by multiple filings and anticipates several additional filings to support their technology.

Technology

Somatostatin (also known as Growth Hormone Inhibiting Hormone) is the main regulator for the release of

Growth Hormone Growth hormone (GH) or somatotropin, also known as human growth hormone (hGH or HGH) in its human form, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration in humans and other animals. It is thus important in ...

(GH) from the pituitary gland, which leads to several body functions including an increase of

IGF-1 Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults. In the 1950s IGF-1 was called " sulfa ...

(Insulin-like Growth Factor 1) levels. Somatostatin inhibits the actions of

Growth Hormone-Releasing Hormone Growth may refer to: Biology * Auxology, the study of all aspects of human physical growth * Bacterial growth *Cell growth *Growth hormone, a peptide hormone that stimulates growth *Human development (biology) *Plant growth *Secondary growth, gro ...

, also a hypothalamus hormone, which controls the release of Growth Hormone. Braasch's Somatostatin vaccine technology allows the immune system to temporarily reduce, but not eliminate, the mostly inhibitory actions of Somatostatin. The vaccination effect causes more Growth Hormone to be released, which in turn stimulates the release of IGF-1 from the liver. This hormone cascade can help address issues relating to obesity and Type 2 diabetes, since growth hormone deficiencies can lead to increased risk for those conditions.

Research and development

For human applications, Braasch Biotech is focused on human obesity and Type 2 diabetes applications, along with Growth Hormone deficiencies and IGF-1 disorders. In the veterinary field, Braasch has developed vaccines to increase livestock productivity and reduce obesity in pets (dogs, cats, and horses). The applicability of GH and IGF-1 treatments are currently being pursued by many pharmaceutical companies for a variety of human conditions. Based on the success of drug treatments, over time, Braasch will pursue additional applications and intellectual property for their vaccination approach (e.g. development of

myocardial infarction A myocardial infarction (MI), commonly known as a heart attack, occurs when Ischemia, blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction (tissue death) to the heart muscle. The most common symptom ...

treatments).

References

{{Reflist

External links

Companies based in South Dakota Biotechnology companies established in 2008 2008 establishments in South Dakota Pharmaceutical companies established in 2008